SNIPR BIOME raises $50 million Series A financing to advance CRISPR-based microbiome drugs to human clinical trials

11. March 2019

|In Portfolio News

|By eazee-designstudio

SNIPR BIOME, a leading CRISPR and microbiome private biotech company, today announced a $50 million series A financing led by existing investor Lundbeckfonden Emerge and LSP, together with North-East Family Office and Wellington Partners. SNIPR BIOME is pioneering a novel use of CRISPR/Cas technology to selectively and precisely eradicate target bacteria, while leaving the rest of the patient’s microbial community intact.